US voters will head to the polls next week in the midterm elections, and in the run-up to the election, the Kaiser Family Foundation has revealed that pharmaceutical companies have donated nearly $79 million to members of Congress over the past 6 election cycles.
US voters will head to the polls next week in the midterm elections, and in the run-up to the election, the Kaiser Family Foundation has revealed that pharmaceutical companies have, over the past 6 election cycles, donated nearly $79 million to members of Congress.
These findings come from Kaiser’s newly launched “Pharma Cash to Congress” tool, which uses campaign finance reports from the Federal Election Commission. The interactive tool allows users to explore which lawmakers have received the biggest contributions from pharma, and which companies have given the most. Voters can search for members of congress to find detailed breakdowns of contributions received from individual pharmaceutical companies both in the current election cycle and since 2007.
According to Kaiser, since the beginning of 2017, 34 lawmakers have each received more than $100,000 each from drug makers’ political action committees (PACs), and 2 representatives—Kevin McCarthy, R-California, and Greg Walden, R-Oregon, have accepted more than $200,000 each.
More Republicans (209) than Democrats (185) received contributions, with Republican representatives and senators receiving a total of $4.9 million and $2.1 million, respectively, and Democratic representatives and senators receiving $3.3 million and $1.6 million, respectively, as of June 30, 2018. During the 2010 election cycle, when Democrats were in power, a greater amount of donated dollars went to Democratic lawmakers.
Among companies who contributed the most were Pfizer ($1.02 million), Amgen ($946,000), AbbVie ($852,000), and Abbot Laboratories ($703,000).
Kaiser also notes that donations to lawmakers in election cycles tell only part of the story of pharma’s influence in US politics; its “Pre$cription for Power” tool, released in April of this year, tracked donations to patient advocacy groups that, it says, “provide patients to testify on Capitol Hill and organize social media campaigns on drugmakers’ behalf.”
Kaiser’s research into these donatiosn revealed that pharmaceutical companies gave $116 million to patient groups in 2015 alone, raising concerns that patient groups’ advocacy, and eventually the nation’s health policy, could be negatively impacted by pharma’s dollars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.